Eli Lilly and Peptron remain in an extended technology evaluation phase for the SmartDepot sustained-release microsphere platform, originally signed as a non-exclusive feasibility agreement in October 2024 and prolonged through October 7, 2026, specifically to complete in-vivo studies on Lilly’s peptide candidates. No commercial licensing, technology-transfer, or binding rights-granting deal has been announced despite ongoing joint formulation work, and recent activity shows Peptron advancing its own SmartDepot applications elsewhere while Lilly pursues competing long-acting technologies. Traders therefore assign slightly elevated odds to “No” because the tight remaining window favors further delay or non-qualification over a full commercial resolution by the cutoff.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoNUEVO
NUEVO
7 oct 2026
NUEVO
NUEVO
7 oct 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron remain in an extended technology evaluation phase for the SmartDepot sustained-release microsphere platform, originally signed as a non-exclusive feasibility agreement in October 2024 and prolonged through October 7, 2026, specifically to complete in-vivo studies on Lilly’s peptide candidates. No commercial licensing, technology-transfer, or binding rights-granting deal has been announced despite ongoing joint formulation work, and recent activity shows Peptron advancing its own SmartDepot applications elsewhere while Lilly pursues competing long-acting technologies. Traders therefore assign slightly elevated odds to “No” because the tight remaining window favors further delay or non-qualification over a full commercial resolution by the cutoff.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercado abierto: May 5, 2026, 8:02 PM ET
Volumen
$8,308Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly and Peptron remain in an extended technology evaluation phase for the SmartDepot sustained-release microsphere platform, originally signed as a non-exclusive feasibility agreement in October 2024 and prolonged through October 7, 2026, specifically to complete in-vivo studies on Lilly’s peptide candidates. No commercial licensing, technology-transfer, or binding rights-granting deal has been announced despite ongoing joint formulation work, and recent activity shows Peptron advancing its own SmartDepot applications elsewhere while Lilly pursues competing long-acting technologies. Traders therefore assign slightly elevated odds to “No” because the tight remaining window favors further delay or non-qualification over a full commercial resolution by the cutoff.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volumen
$8,308Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly and Peptron remain in an extended technology evaluation phase for the SmartDepot sustained-release microsphere platform, originally signed as a non-exclusive feasibility agreement in October 2024 and prolonged through October 7, 2026, specifically to complete in-vivo studies on Lilly’s peptide candidates. No commercial licensing, technology-transfer, or binding rights-granting deal has been announced despite ongoing joint formulation work, and recent activity shows Peptron advancing its own SmartDepot applications elsewhere while Lilly pursues competing long-acting technologies. Traders therefore assign slightly elevated odds to “No” because the tight remaining window favors further delay or non-qualification over a full commercial resolution by the cutoff.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes